BAYER AG

Major pharmaceutical companies including AstraZeneca, Novartis, and Astellas are defending patents for blockbuster drugs like Lynparza, Entresto, and Xtandi against generic manufacturers in early 2025.

Bayer and Kumquat Biosciences announced an exclusive global license and collaboration worth up to $1.3 billion to develop a KRAS G12D inhibitor targeting pancreatic, colorectal, and lung cancers.

The German Federal Patent Court revoked Bayer's crucial Xarelto patent EP 1 845 961 due to lack of inventive step, contradicting its earlier 2024 opinion that assumed the patent's validity.

Artbio secured $132 million in Series B funding to advance AB001, a lead-212 based radiopharmaceutical targeting metastatic castration-resistant prostate cancer.

Intellectual property experts warn that the India-UK Free Trade Agreement may weaken compulsory licensing mechanisms, a critical tool for ensuring access to affordable life-saving medicines during public health emergencies.

Daré Bioscience announced positive interim safety and efficacy results from its Phase 3 trial of Ovaprene, an investigational monthly hormone-free intravaginal contraceptive.

Daré Bioscience received a $6 million non-dilutive grant installment, bringing total funding to $37.8 million of up to $49 million committed for DARE-LARC1 contraceptive development.

RedHill Biopharma has initiated patient recruitment for a Phase 2 study evaluating opaganib plus darolutamide in men with metastatic castrate-resistant prostate cancer, sponsored by ANZUP and supported by Bayer.

AbbVie has agreed to acquire cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion in cash, gaining access to innovative in vivo CAR-T technology.

Bayer and Tsinghua University have extended their strategic research collaboration by three additional years, building on a 16-year partnership that has produced over 70 joint research projects and more than 10 publications in top international journals.